BCAB · BioAtla, Inc.
$3.09
-0.36 (-10.43%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, and along with our history of operating losses, our current cash and cash equivalents are not sufficient to fund our ongoing operations for a period of at least twelve months from the date the condensed consolidated financial statements included in this report are issued, and these circumstances raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.15M
Shares
1.67M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$300K
FY2021
Net Income
-$59.61M
+14.6%
FY2025
Operating Margin
-32146.67%
FY2021
Diluted EPS
-$50.50
+29.9%
FY2025
Operating Cash Flow
-$48.2M
+33%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $300K | — | — | |
| $25.46M | $43.57M | $63.1M | $103.73M | $79.35M | $58.27M | $19.93M | $25.92M | |
| $15.17M | $17.73M | $21.85M | $25.96M | $28.79M | $38.42M | $10.6M | $7.55M | |
| — | $373K | $925K | $1.22M | $1.2M | $1.33M | $1.01M | $860K | |
| $40.63M | $61.31M | $84.94M | $129.69M | $108.14M | $96.69M | $30.53M | $33.47M | |
| -$32.13M | -$59.31M | -$73.94M | -$129.69M | -$108.14M | -$96.44M | -$30.1M | -$28.27M | |
| — | — | — | — | — | -32146.67% | — | — | |
| — | -$58.93M | -$73.02M | -$128.47M | -$106.94M | -$95.11M | -$29.09M | -$27.41M | |
| — | — | — | — | $0 | $3000 | $1.39M | $1.63M | |
| $263K | $843K | $3.37M | $6.31M | $1.65M | $350K | $100K | $128K | |
| $671K | -$302K | $4.17M | $6.23M | $1.66M | $1.04M | -$5.75M | -$1.59M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$31.45M | -$59.61M | -$69.78M | -$123.46M | -$106.48M | -$95.4M | -$35.85M | -$29.86M | |
| — | — | — | — | — | -31800.67% | — | — | |
| — | — | — | — | — | $0 | $0 | -$61K | |
| USD/shares | — | -$50.50 | -$72.00 | -$129.00 | -$137.00 | -$138.00 | — | — |
| USD/shares | — | -$50.50 | -$72.00 | -$129.00 | -$137.00 | -$138.00 | — | — |
| shares | — | 1.18M | 971.47K | 955.55K | 778.55K | 691.22K | 168.56K | — |
| shares | — | 1.18M | 971.47K | 955.55K | 778.55K | 691.22K | 168.56K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.39×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 156 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1826892
CUSIP
09077B203
13F (30d)
21 filings
21 filers
Visit website
Investor relations